+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Recurrent anaplastic astrocytomas - Pipeline Insight, 2021

  • ID: 5306350
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Curis, Inc.
  • Hoffmann-La Roche
  • OncoSynergy, Inc.
  • Orbus Therapeutics
  • Xenova Biomedix
This “Recurrent anaplastic astrocytomas - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Recurrent anaplastic astrocytomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Recurrent anaplastic astrocytomas Understanding

Recurrent anaplastic astrocytomas: Overview

Anaplastic astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. Astrocytomas come in four grades based upon how fast the cells are reproducing and that likelihood that they will spread (infiltrate) nearby tissue. The symptoms of anaplastic astrocytoma vary depending upon the exact location and size of the tumor. Symptoms commonly associated with anaplastic astrocytomas include headaches, lethargy or drowsiness, vomiting, and changes in personality or mental status. The exact cause of anaplastic astrocytomas is unknown. Researchers speculate that genetic and immunologic abnormalities, environmental factors (e.g., exposure to ultraviolet rays, certain chemicals, and ionizing radiation), diet, stress, and/or other factors may play contributing roles in causing specific types of cancer.

"Recurrent anaplastic astrocytomas - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent anaplastic astrocytomas pipeline landscape is provided which includes the disease overview and Recurrent anaplastic astrocytomas treatment guidelines. The assessment part of the report embraces, in depth Recurrent anaplastic astrocytomas commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent anaplastic astrocytomas collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Recurrent anaplastic astrocytomas R&D. The therapies under development are focused on novel approaches to treat/improve Recurrent anaplastic astrocytomas.

Recurrent anaplastic astrocytomas Emerging Drugs Chapters

This segment of the Recurrent anaplastic astrocytomas report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Recurrent anaplastic astrocytomas Emerging Drugs

Eflornithine: Orbus Therapeutics, Inc.

Eflornithine is ornithine decarboxylase inhibitors investigational product. The drug is in phase III clinical trial for the treatment of anaplastic astrocytoma. Eflornithine has been received orphan drug designation for the anaplastic astrocytoma.

Fimepinostat: Curis, Inc.

Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. Fimepinostat is being studied in phase I stage of development for the treatment of anaplastic astrocytoma.

Recurrent anaplastic astrocytomas: Therapeutic Assessment

This segment of the report provides insights about the different Recurrent anaplastic astrocytomas drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Recurrent anaplastic astrocytomas

There are approx. 5+ key companies which are developing the therapies for recurrent anaplastic astrocytomas. The companies which have their recurrent anaplastic astrocytomas drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics, Inc.

Phases

This report covers around 5+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Recurrent anaplastic astrocytomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Recurrent anaplastic astrocytomas: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Recurrent anaplastic astrocytomas therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent anaplastic astrocytomas drugs.

Recurrent anaplastic astrocytomas Report Insights
  • Recurrent anaplastic astrocytomas Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Recurrent anaplastic astrocytomas Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Recurrent anaplastic astrocytomas drugs?
  • How many Recurrent anaplastic astrocytomas drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent anaplastic astrocytomas?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Recurrent anaplastic astrocytomas therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Recurrent anaplastic astrocytomas and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Curis, Inc.
  • Hoffmann-La Roche
  • OncoSynergy, Inc.
  • Orbus Therapeutics
  • Xenova Biomedix
Introduction

Executive Summary

Recurrent anaplastic astrocytomas: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Recurrent anaplastic astrocytomas - Analytical Perspective

In-depth Commercial Assessment
  • Recurrent anaplastic astrocytomas companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Recurrent anaplastic astrocytomas Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Preregistration)
  • Comparative Analysis
Eflornithine: Orbus Therapeutics, Inc.
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Encorafenib: Pfizer
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Fimepinostat: Curis, Inc.
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical Stage Products
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Recurrent anaplastic astrocytomas Key Companies

Recurrent anaplastic astrocytomas Key Products

Recurrent anaplastic astrocytomas- Unmet Needs

Recurrent anaplastic astrocytomas- Market Drivers and Barriers

Recurrent anaplastic astrocytomas- Future Perspectives and Conclusion

Recurrent anaplastic astrocytomas Analyst Views

Recurrent anaplastic astrocytomas Key Companies

Appendix

List of Tables
Table 1 Total Products for Recurrent anaplastic astrocytomas
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Recurrent anaplastic astrocytomas
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Orbus Therapeutics
  • OncoSynergy, Inc.
  • Xenova Biomedix
  • Curis, Inc.
  • Hoffmann-La Roche
Note: Product cover images may vary from those shown
Adroll
adroll